Introduction: Leadless cardiac pacemaker (LCP) implantation using a transcatheter was recently developed to avoid pocket-and lead-related complications. Although a LCP has an active fixation mechanism using tines or a helix, LCP and lead dislodgement issues remain a major safety concern for patients. This article reviews the literature to determine the incidence of lead and LCP dislodgement.
INTRODUCTION
Since their introduction in the late 1950s, cardiac pacemaker (PM) and lead technology have markedly improved, and include a reduction in generator size and lead diameter, increased battery longevity, electrode quality, and durability. 1 The implantation of transvenous endocardial leads is a safe and relatively simple procedure, although effective lead placement is still a critical part of the procedure. Nearly 1 million patients worldwide receive transvenous cardiac PMs to treat bradycardia and heart block each year. 2 However, despite the technological advancements in PMs, lead dislodgement is still one of the most common complications.
It is known that traditional PM and lead systems are subject to infection and lead failure. To avoid pocket-and lead-related complications, two leadless cardiac pacemaker (LCP) systems have been developed to meet this clinical requirement. 3 As the LCP is implanted with a relatively large delivery transcatheter through the femoral vein using active fixation, the device and/or electrode dislodgement remains a major safety concern with this new technique.
This study aimed to provide a detailed analysis of the available literature on the incidence of lead electrode dislodgement with conventional PMs compared with the incidence observed in recently published LCP trials. Additionally, reasons for lead and device dislodgement were analyzed. 
Study retrieval strategy
A systematic search of the PubMed, Cochrane Library, and Google Scholar databases was performed from 1990 to 2018. Only fullsized papers in English, published in peer-reviewed journals, reporting detailed data on the most common PM lead-related complications were considered. Studies eligible for inclusion were identified using the following search strategy: 1 st run: "pacemaker," 2 nd run: (dislodgement or dislocation) and "PM." According to the inclusion criteria and exclusion criteria, the flowchart of literature selection is shown in Figure 1. 
Inclusion criteria
The eligibility criteria for this meta-analysis were as follows. 
Exclusion criteria
(1) Studies reporting only pooled data for PM, coronary sinus or implantable cardioverter-defibrillator leads associated complications were not considered. (2) Studies using repeated clinical data were not considered. (3) Studies or reviews with no direct data were not considered.
Data extracted
The total number of patients, the number of patients with dislodgement, patient characteristics, frequency and timing of lead dislodgement, utilized lead and system types, and rate of dislodgement were extracted from the selected studies. The methodological quality of noncontrolled studies was assessed using the Methodological Index for Nonrandomized Studies (MINORS). 4 Studies were defined to be of low, moderate, or high quality based on their MINORS scores of ≤8, 9-16, and ≥17 points, respectively.
The methodological quality of randomized controlled studies was assessed using the Cochrane risk bias assessment tool. The risk of bias was evaluated mainly from six areas of the project team, and judgment was carried out on each indicator using "low bias risk," "moderate bias risk," and "high bias risk."
Statistical analysis
Statistical analyses were conducted using R 3.3 (Biostat, Inc., Englewood, NJ, USA) and Microsoft Excel 2016 MSO (Microsoft Corp., Redmond, WA, USA). Event rates were synthesized using descriptive statistics; minimum and maximum, mean, weighted mean, and median incidences were calculated. Odds ratio (OR) and its 95% confidence intervals (CIs) were calculated from events and sample sizes for a head-to-head comparison of different systems and lead types or lead positions. Heterogeneity between individual trial estimates was assessed using the Q statistic and I 2 statistic. In the case of I 2 index values > 50% indicating significant heterogeneity, the random-effect model was used, otherwise the fixed-effect model was used.
RESULTS

Study characteristics
A total of 18 studies fulfilled the predefined selection criteria for leads and three studies fulfilled the criteria for LCP devices.
These studies included 17,321 patients undergoing conventional single-or dual-chamber PM implantation ( Figure 1 ; Table 1) and 2,046 patients for a LCP device (Table 2) . Of the identified studies, only one 7 was a randomized controlled clinical trial, whereas the remainder were post hoc analyses of randomized trials, 17, 24 or observational retrospective 5, 8, 16, 18, 22, 23 or observational prospective studies. [9] [10] [11] [12] [13] [14] [15] [19] [20] [21] 25 The vast majority were multicenter studies, 5, 12, 13, 15, 17, [20] [21] [22] 24, 25 with seven single-center studies. 9, 11, 13, 16, 18, 19, 23 Individual studies used different definitions of lead dislodgement or dislocation including signs of elevated pacing thresholds or a decrease in sensing or failure to capture, or a visible change in lead position on chest x-ray (Tables 1 and 2 ). 
TA B L E 1 Characteristics of conventional pacemaker systems in the included studies
Subjects
Lead dislodgement with conventional PM systems
The incidence of lead dislodgement ranged from 1% to 2.69% in individual studies with a mean of 1.63%, weighted mean of 1.71%, and median of 1.60% (Figure 2 ). In the present review, lead dislodgement was the most common complication of conventional PM systems.
There was a relatively higher lead dislodgement rate with atrial as compared to ventricular electrodes (OR, 3.56; 95% CI, 1.9-6.70; P = 0.6; I 2 = 0%) and between MRI conditional and conventional leads 
Device dislodgement with LCP systems
The incidence of LCP device dislodgement was 0%, 0.13%, and 1.1%
in three leadless PM studies (Figure 2) . 12, 13, 25 In the second MICRA study, one local device dislodgement (without embolization) was noted 2 days postimplant, and in this case, two tines were observed to not be embedded in tissues and two tines were positioned between the wall and papillary muscle. Fortunately at 50 days postimplant, the same device was successfully repositioned, with normal pacing thresholds and no further issues noted at the time of repositioning. 12 In the Nanostim study, device migration to the pulmonary artery or right femoral vein occurred in four and two patients, respectively. There was no significant difference in the dislodgement rate between devices positioned in the right ventricular apex and those in nonapical positions (P = 0.42) in the total cohort of 526 patients. 13 
DISCUSSION
Main findings
Eighteen studies which included 17,321 patients undergoing conventional single-or dual-chamber PM implantation showed an overall high incidence of lead dislodgement (on average > 1.5%). In the LCP studies, the dislodgement incidence of MICRA was 0% and 0.13%, respectively, and the dislodgement incidence of Nanostim was 1.1%. These values were all lower than the traditional PM lead dislodgement risk, reflecting the significant potential of this new technology. 
Incidence of lead dislodgement with conventional PM systems
As shown in Figure 3 (A), Ghani et al. 19 reported an atrial electrode dislodgement rate that is sevenfold higher than that of ventricular dislodgement. Most studies showed that the dislodgement rate of atrial electrodes was slightly higher than that of ventricular electrodes.
This may be due to the thin wall and the anatomical location of the right atrial appendage, the most targeted site for RA lead placement.
The results in Figure 3(B) show that the type of lead fixation design also had some influence on electrode dislodgement. The rate of lead dislodgement in the active fixation design was lower. The active fixation leads, with a screw-in mechanism, conceptually were purported to provide more consistent contact with myocardial tissue and prevent dislodgement, thus leading to a lower incidence of high pacing threshold or loss of capture events. One-year follow-up data from Witt et al. 8 showed that lead dislodgement in the active fixation method was similar to that in passive fixation. However, after a 5-year follow-up period, the rate of lead dislodgement in active fixation was significantly lower than that in passive fixation.
As shown in Figure 3(C) , the results from Elmouchi et al. demonstrated that the rate of MRI conditional lead dislodgement was 13.54 times higher than that of non-MRI-conditional lead dislodgement.
This may be attributed to the different skill level of the implanter, which can result in instability of the electrode implanted. For example, a study reported that two implanting physicians both had two lead dislodgements, whereas the remaining three electrophysiologists had no dislodgements. 23 The higher rate of dislodgement between the 5,086 MRI conditional lead and the 5,076 lead may be due to the reduced filar design, the slightly increased lead weight, and physician learning curve during implantation of this active fixation lead. 24 
Device dislodgement with LCP systems
This study showed that dislodgement of LCP occurs at a lower magnitude compared to transvenous leads dislodgement. While there is no head-to-head randomized comparison, it appears that dislodgement rate of Micra is lower than Nanostim. Conceivably, the active nitinol tines allow a more stable position as compared to the Nanostim helix active fixation. Targeting at least two to four tines for engagement within the myocardium gives the implanting physician a visible landmark that helps ensure stability of the PM.
LIMITATIONS
We did not have access to individual patient data from all the studies reviewed but relied on published information. Furthermore, there were large variations in the follow-up periods, and no long-term followup data were available in some of the studies. LCP systems represent single-chamber devices only and patient populations were limited; therefore, the comparison of complications with dual-chamber systems could be biased.
CONCLUSIONS
Dislodgement rates of conventional PM leads vary in individual studies with an overall high incidence. Use of the currently available LCP systems appears to result in a lower rate of lead dislodgement. This may reflect the effectiveness of this novel technology and the design of these devices. A better classification scheme of device dislodgement would be advantageous for future research. Despite the lack of longterm data, results from these studies showed that leadless pacing therapy is an efficacious and safe alternative to conventional PMs.
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